For individuals with symptomatic illness necessitating therapy, ibrutinib is usually proposed based on 4 phase III randomized scientific trials evaluating ibrutinib with chlorambucil monotherapy106 and other typically applied CIT mixtures, namely FCR, bendamustine furthermore rituximab and chlorambucil moreover obinutuzumab (ClbO).107–109 Ibrutin